PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.310
https://www.valueinhealthjournal.com/article/S1098-3015(19)32688-9/fulltext
Title :
PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32688-9&doi=10.1016/j.jval.2019.09.310
First page :
Section Title :
Open access? :
No
Section Order :
10251